Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Resource Library

A Novel Paradigm and New Drug for the Management of Ductus-Dependent Congenital Heart Disease

L Ye

M Li

X Ye

C Jiang

H Chen

H Zhang

Jinfen Liu

H Hong

X Yan

X Liu

Reviews

  Sign in to add a review

0 comments
Leave a Comment

Conference: 2018 PHA International PH Conference & Scientific Sessions

Release Date: 07.28.2018

Presentation Type: Abstracts

File Download: 2018 Conference Abstract 1001

Download Adobe Acrobat

2018 International PH Conference and Scientific SeAbstract presented at the 2018 International PH Conference and Scientific Sessions in Orlando, Fla., June 28-July 1, 2018.

Background

Proper management of ductus-dependent congenital heart disease (CHD) is always a great concern to pediatricians. Our previous study suggested MEK1/2 may play a role in the regulation of ductus arteriosus (DA) patent or constricted. Here, we present the mechanism’s study of MEK1/2 pathway on DA patency and that whether MEK1/2 inhibitor PD0325901 has therapy potentiality for keeping DA patency.

Methods

MEK1/2 expression in patent and constricted human DA tissues was measured and MEK1/2 pathway inhibition with respect to DA patency was tested in a mouse model via postnatal or prenatal administration of MEK1/2 inhibitor, PD0325901. Mechanisms of MEK1/2 inhibition and DA patency were explored in human DA smooth muscle cells (DASMCs).

Results

Data indicated that MEK1/2 was differentially expressed between constricted and patent DA tissues. Post- or prenatal administration of PD0325901 maintained DA patency during the postnatal period. MEK1/2 inhibition may promote DA patency by reducing cytosolic calcium in DASMCs, which is associated with DA functional closure, and reducing the proliferation and migration of DASMCs, which is associated with DA anatomic closure.

Conclusions

MEK1/2 pathway may simultaneously regulate both functional and anatomic closure of DA. MEK1/2 inhibitor PD0325901 may hold therapeutic promise to keep DA patency.

 

Figure 1: Expression of MEK1/2 and its phosphorylated MEK1/2(p-MEK1/2), in patent and constricted DAs

Figure 2: The effectiveness of PD0325901 in maintaining DA patency

Figure 3: The mechanism of PD0325901-mediated DA patency

 Figure 4: Schematic diagram of MEK1/2 signaling pathways and modulators regulating DASMC contraction, proliferation and migration